Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth

References

• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: ‘Metronomic’ dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–7
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of ‘metronomic’ chemotherapy. Nature Rev Cancer 2004; 4: 423–6
   PubMed Web of Science ®Google Scholar
• du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12: 904–16
   PubMed Web of Science ®Google Scholar
• Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy. Clin Cancer Res 2005; 11: 6678–85
   PubMed Web of Science ®Google Scholar
• Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 5190–8
   PubMed Web of Science ®Google Scholar
• Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006; 15: 225–35
   Google Scholar
• Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938–43
   PubMed Web of Science ®Google Scholar
• Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003; 14: 13–9
   PubMed Web of Science ®Google Scholar
• Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003; 9: 1323–32
   PubMed Web of Science ®Google Scholar
• Bell IM, Gallicchio SN, Abrams M, Beshore DC, Buser CA, Culberson JC, et al. Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)–2–oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrroli- dinone farnesyltransferase inhibitor with excellent cell potency. J Med Chem 2001; 44: 2933–49
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–R24
   PubMed Web of Science ®Google Scholar
• Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination ‘metronomic’ chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002; 8: 221–32
   PubMed Web of Science ®Google Scholar
• Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005; 97: 1272–86
   PubMed Web of Science ®Google Scholar
• Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 2003; 100: 15871–6
   PubMedGoogle Scholar
• Webb JL. Enzyme and metabolic inhibitors. Academic Press, New York 1963; 150–153
   Google Scholar
• Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin-1, a mediator of the anti-angiogenic effects of low dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003; 100: 12917–22
   PubMed Web of Science ®Google Scholar
• Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, Plym-Forshell G. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. Eur J Clin Pharmacol 1984; 26: 113–9
   PubMed Web of Science ®Google Scholar
• Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol 2002; 20: 1115–27
   PubMedGoogle Scholar
• Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997; 3: 1093–100
   PubMed Web of Science ®Google Scholar
• Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58: 4363–7
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646–62
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–86
   PubMed Web of Science ®Google Scholar
• Funovics P, Brostjan C, Nigisch A, Fila A, Grochot A, Mleczko K, et al. Effects of 15d-PGJ(2) on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells. Prostaglandins Other Lipid Mediat 2006; 79: 230–44
   PubMed Web of Science ®Google Scholar
• Nimi Y, Mochida S, Matsui A, Inao M, Fujiwara K. PKC- and MAPK-independent upregulation of VEGF receptor expressions in human umbilical venous endothelial cells following VEGF stimulation. Hepatol Res 2001; 21: 261–7
   PubMedGoogle Scholar
• Morqillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006; 15: 709–19
   PubMedGoogle Scholar
• Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro. Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci USA 1990; 87: 7926–9
   PubMed Web of Science ®Google Scholar
• Gu WZ, Joseph I, Wang YC, Frost D, Sullivan GM, Wang L, et al. A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies. Anticancer Drugs 2005; 16: 1059–69
   PubMed Web of Science ®Google Scholar
• Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 653–61
   PubMed Web of Science ®Google Scholar
• Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22: 3631–8
   PubMed Web of Science ®Google Scholar